Currently, combination therapy using trastuzumab and conventional chemotherapeutic agents were recommended as first line therapy for the management of HER2 positive breast cancer, which significantly improves patient outcomes [7, 8]. The gene discussed is ERBB2; the disease is breast carcinoma.